Gunhild Keller

发表

BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC

J. Becker, S. Ugurel, D. Schrama, 2008, Journal of carcinogenesis.

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations

A. Schally, J. Engel, Gunhild Keller, 2006, Proceedings of the National Academy of Sciences.

Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.

A. Schally, K. Groot, Gabor L. Toller, 2005, The Journal of clinical endocrinology and metabolism.

Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215

A. Schally, J. Engel, Gunhild Keller, 2005, Clinical Cancer Research.

Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.

A. Schally, J. Engel, Gunhild Keller, 2005, Fertility and sterility.

Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model

T. Brümmendorf, J. Schrader, A. Lohse, 2012, Clinical Cancer Research.

Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors

A. Schuppert, H. Pospisil, S. Venz, 2013, PloS one.

Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy

T. Brümmendorf, Gunhild Keller, M. Braig, 2009, Hematological oncology.

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia

Gunhild Keller, P. Schafhausen, T. Brummendorf, 2009, Expert review of hematology.

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.

C. Bokemeyer, T. Brümmendorf, S. Balabanov, 2007, Leukemia research.

Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro

R. Bosotti, Christine Barett, C. Bokemeyer, 2011, PloS one.

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.

S. Balabanov, A. Quaas, J. Schrader, 2009, Neoplasia.

Multi tyrosine kinase inhibitor dasatinib as novel cause of pulmonary artery hypertension ?

C. Bokemeyer, T. Brümmendorf, H. Baumann, 2010 .

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

C. Bokemeyer, T. Brümmendorf, S. Balabanov, 2008, Blood.

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, Gabor L. Toller, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)

A. Schally, K. Szepesházi, Gunhild Keller, 2012, Oncotarget.

Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.

A. Schally, J. Engel, Gunhild Keller, 2005, Endocrine-related cancer.

Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.

A. Schally, J. Engel, Gunhild Keller, 2006, International journal of oncology.

Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.

A. Schally, J. Engel, Gunhild Keller, 2005, Cancer research.

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

D. Schadendorf, J. Becker, S. Ugurel, 2008, Cancer Immunology, Immunotherapy.

Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues

A. Schally, J. Engel, Gunhild Keller, 2005, Clinical Cancer Research.

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

C. Bokemeyer, T. Brümmendorf, H. Baumann, 2011, BMC pulmonary medicine.

Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.

A. Schally, J. Engel, Gunhild Keller, 2005, European journal of cancer.

Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1

A. Schally, J. Engel, Gunhild Keller, 2005, Cancer.

Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.

A. Schally, J. Engel, Gunhild Keller, 2005, European journal of cancer.

Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 can overcome chemoresistance in experimental renal cell carcinomas

A. Schally, J. Engel, Gunhild Keller, 2005, Cancer.

Growth inhibition of experimental non‐Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN‐238

A. Schally, J. Engel, Gunhild Keller, 2005, International journal of cancer.

Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin’s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207

A. Schally, J. Engel, Gunhild Keller, 2005 .

Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues

A. Schally, J. Engel, Gunhild Keller, 2005, Clinical Cancer Research.

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations

A. Schally, J. Engel, Gunhild Keller, 2006, Proceedings of the National Academy of Sciences.